Exentis Group AG provides the 3D technology platform that enables industrial large-scale production of both industrial and clean room applications. The strategic cooperation currently agreed between Laxxon Medical and Hovione combines Laxxon Medical’s expertise in pharmaceutical applications with Hovione’s product and process development, engineering and manufacturing expertise.
Under the terms of the agreement, Hovione will initially establish the Exentis 3D technology platform for industrial clean room production at its manufacturing facilities in Portugal and subsequently at its manufacturing facilities in New Jersey, USA. The latest generation of Exentis clean room 3D production systems to be used are modularly extendable and can be scaled up to capacities of millions of tablets per day.
Compared to conventional tablets, the innovative tablets which are mass-produced using Exentis 3D technology have a freely adjustable release profile for the active pharmaceutical ingredients within the human body.
Dr. Gereon Heinemann, CEO of Exentis Group AG: “Together with Laxxon Medical, our long-standing 3D community member, we were able to convince Hovione of the performance of our Exentis 3D technology platform. The strategic cooperation will further accelerate the broad deployment of our clean room 3D technology and production systems within the pharmaceutical industry.”
Find out more about Laxxon Medical at laxxonmedical.com.
For more information about Hovione, please visit hovione.com.
Subscribe to our Newsletter
3DPResso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
